Skip to main content

Vasculitis

In case you missed it: FDA Approves Avacopan for ANCA-Associated Vasculitis https://t.co/L7UwhYBaVY #RheumNow https://t.co/HypjLMLwjU
Dr. John Cush @RheumNow( View Tweet )
Oct 16, 2021

RheumNow Podcast – Quackademia (10.15.2021)

Oct 14, 2021

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
FDA Approves Avacopan for ANCA-Associated Vasculitis https://t.co/L7UwhYBaVY #RheumNow https://t.co/0cGN5eyfCl
Dr. John Cush @RheumNow( View Tweet )
Oct 12, 2021

FDA Approves Avacopan for ANCA-Associated Vasculitis

Oct 11, 2021

October 8, 2021 the U.S. Food and Drug Administration (FDA) approved avacopan (trade name: Taveneos), an oral complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis). It is

Read Article
Encouraging DBRPCT of Rituximab in #PMR: 116 screened, 49 enrolled, 47 completed: 23 on RTX vs 24 on PBO. Steroid-free remission at 21 wks seen with 11/23 (48%) RTX pts vs 5/24 (21%) on PBO (p=0·049). Infusion Rxns: 10 RTX vs 3 PBO); 1 SAE (PE) on RTX https://t.co/U2ZGNrpi0i

Dr. John Cush @RheumNow( View Tweet )

Sep 24, 2021

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
The EMA has recommended Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/0aVoDpaTPT

Dr. John Cush @RheumNow( View Tweet )

Sep 23, 2021
Metanalysis of long-term steroid (GC) in PMR (24 studies) 77%, 51%, & 25% PMR pts still GC respectively 1, 2, & 5 yrs. 1st Yr pooled relapse rate =43%. Prolonged GC use/relapse moreso in Females, Hi ESR, periph arthritis, starting dose, tapering speed https://t.co/n0gGlik1hO https://t.co/WBqdfUW2RS
Dr. John Cush @RheumNow( View Tweet )
Sep 01, 2021

TNF Inhibitor Induced IgA Vasculitis in IBD

Aug 31, 2021

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.



A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Read Article
Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN

Dr. John Cush @RheumNow( View Tweet )

Aug 27, 2021

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Aug 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.




  1. In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Read Article

Mepolizumab Dosing in Eosinophilic Granulomatosis with Polyangiitis

Aug 11, 2021

A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome). 

Read Article

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Aug 06, 2021

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
Article in press: Can ANCA titers predict relapse in patients with GPA? Cohort study by @UofT_DoM - microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse https://t.co/ks3Gj5iSLR

Seminars in Arthritis and Rheumatism @seminarthrheum( View Tweet )

Aug 02, 2021
ICYMI: One of our top June videos WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j
Dr. John Cush @RheumNow( View Tweet )
Aug 01, 2021
ICYMI: Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w0IGAx

Dr. John Cush @RheumNow( View Tweet )

Jul 30, 2021
ICYMI: EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Dr. John Cush @RheumNow( View Tweet )

Jul 29, 2021
ICYMI While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/sJpbzIbBJt
Dr. John Cush @RheumNow( View Tweet )
Jul 29, 2021
While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/v3KhEaefZD
Dr. John Cush @RheumNow( View Tweet )
Jul 22, 2021
Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w10hs5

Dr. John Cush @RheumNow( View Tweet )

Jul 20, 2021

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

Jul 19, 2021

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and

Read Article
ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis Chung et al have published the 2021 treatment guidelines for the management of antineutrophil cytoplasmic antibody–AAV, including GPA, MPA, and EGPA. https://t.co/234OQ7klRd https://t.co/33sWq1U55T
Dr. John Cush @RheumNow( View Tweet )
Jul 15, 2021

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis

Jul 14, 2021

Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the

Read Article
Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable) https://t.co/uph9Eprlvc https://t.co/FPLOgzZpfB
Dr. John Cush @RheumNow( View Tweet )
Jul 08, 2021
Textbooks say fever is common in lupus ("36%–86%") BUT IT IS NOT! Lupus is cause of FUO in 5%; Fever is seen in a minority of SLE onsets; Fever occurs w/ SLE complications - vasculitis, pneumonitis/serositis/alveolar hem, CNS, & INFECTION! https://t.co/KvZeo6Q1WY

Dr. John Cush @RheumNow( View Tweet )

Jul 07, 2021
×